Quick Answer
Theravance Biopharma, Inc. reported Stockholders Equity of $296.72 million for the year ending 2025.
- Theravance Biopharma, Inc. showed an increase of +69.0% in Stockholders Equity from 2024 to 2025.
- This data is from Theravance Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$17.92 million | Q2 2014: $384.76 million | Q3 2014: $339.82 million | Q1 2015: $289.12 million | Q2 2015: $257.67 million | Q3 2015: $222.55 million | Q1 2016: $238.54 million | Q2 2016: $321.58 million | Q3 2016: $297.87 million | Q1 2017: $293.95 million | Q2 2017: $241.13 million | Q3 2017: $184.12 million | Q1 2018: $63.41 million | Q2 2018: $34.39 million | Q3 2018: -$13.45 million | Q1 2019: -$113.25 million | Q2 2019: -$137.22 million | Q3 2019: -$182.81 million | Q1 2020: -$157.94 million | Q2 2020: -$202.34 million | Q3 2020: -$261.54 million | Q1 2021: -$373.22 million | Q2 2021: -$300.37 million | Q3 2021: -$323.59 million | Q1 2022: -$351.45 million | Q2 2022: -$349.81 million | Q3 2022: $480.58 million | Q1 2023: $370.56 million | Q2 2023: $280.16 million | Q3 2023: $246.13 million | Q4 2023: $213.00 million | Q1 2024: $204.87 million | Q2 2024: $193.69 million | Q3 2024: $185.65 million | Q1 2025: $165.98 million | Q2 2025: $224.85 million | Q3 2025: $232.68 million.
- Over the full 15 years of available data (2011 to 2025), Theravance Biopharma, Inc.'s Stockholders Equity has grown by 310.9%.
- Historical annual values: Fiscal year 2025: $296.72 million | Fiscal year 2024: $175.55 million | Fiscal year 2023: $213.00 million | Fiscal year 2022: $441.80 million | Fiscal year 2021: -$338.57 million | Fiscal year 2020: -$303.75 million | Fiscal year 2019: -$223.84 million | Fiscal year 2018: -$51.59 million | Fiscal year 2017: $115.18 million | Fiscal year 2016: $350.23 million | Fiscal year 2015: $243.07 million | Fiscal year 2014: $289.79 million | Fiscal year 2013: -$17.04 million | Fiscal year 2012: -$6.99 million | Fiscal year 2011: -$140.72 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: